Premium
Aberrant Myeloid Marker Expression in Precursor B‐Cell and T‐Cell Leukemias
Author(s) -
Suggs Jeanann L.,
Cruse Julius M.,
Lewis Robert E.
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a384-c
Subject(s) - cd33 , cd117 , myeloid , myeloid leukemia , immunophenotyping , cancer research , b cell , immunology , antigen , biology , medicine , antibody , genetics , cd34 , stem cell
The World Health Organization (WHO) characterization of the immunophenotype of precursor B‐cell acute lymphoblastic leukemia (BALL)/lymphoblastic lymphoma (LBL) includes the possible expression of myeloid cluster of differentiation (CD) markers CD13 and CD33. In precursor T‐cell ALL/LBL, myeloid markers CD13 and CD33 are frequent while CD117 is rare. In the present investigation, 58 cases of confirmed precursor B‐cell ALL/LBL were evaluated for the presence of CD13, CD33 and CD117. Of the 13 (22.4%) cases that positively expressed myeloid markers, 8 (62%) expressed CD13; 10 (77%) expressed CD33; and 1 (8%) expressed CD117. Four (31%) expressed both CD13 and CD33, and 1 (8%) expressed CD13, CD33, and CD117. 18 cases of confirmed precursor T‐cell ALL/LBL were analyzed for myeloid markers CD13, CD33, CD117 and MPO. Of the 5 (28%) expressing myeloid markers, 3 (60%) were positive for CD13; 3 (60%) for CD33; 3 (60%) for CD117; and 1 (20%) for MPO. One (20%) was positive for both CD13 and CD117; 1 (20%) for CD13, CD33 and CD117; and 1 (20%) for CD13, CD33 and MPO. These markers portend a poor prognosis compared to ALL/LBL cases without myeloid antigens, and a poor response to drug therapies targeting conventional ALL/LBL. Future studies will be directed to correlation of these markers with prognosis and therapeutic response, as well as whether drug therapies targeting myeloid antigens could be of use in treatment.